Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Washington University v. Wisconsin Alumni Research Foundation (D. Del. 2013)

See Plans and Pricing

« Back to Dashboard

Washington University v. Wisconsin Alumni Research Foundation (D. Del. 2013)

Docket   Start Trial Date Filed 2013-12-26
Court District Court, D. Delaware Date Terminated 2016-01-25
Cause 28:1332 Diversity-Breach of Contract Assigned To Gregory Moneta Sleet
Jury Demand Plaintiff Referred To
Patents 5,246,925; 5,587,497; 5,597,815
Attorneys Abigail Lubow; Andrew Colin Mayo; David R. Cross; Elizabeth C. Miller; J. Michael Jakes; James R. Gilfoil; Jennifer K. Robinson; John G. Day; Krista E. Bianco; Michael A. Jacobs; Michael A. Morin; Robert F. Shaffer; Shana K. Cyr; Thomas J. Curry
Firms Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Washington University v. Wisconsin Alumni Research Foundation
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Washington University v. Wisconsin Alumni Research Foundation (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-12-26 1 with respect to licensing U.S. Patent No. 5,597,815 (the “’815 Patent”), jointly owned by Washington …815 PATENT ISSUES l7. WARF prosecuted the ’815 Patent Application and obtained the ’8 l 5 Patent, which… to 31 other patents - comprising 30 patents not subject to the IIA, plus the ’8l5 Patent - which it labeled…compound” patents further implied that Zemplar practiced those patents, not the ’8l5 Patent. Washington…multiple lawsuits to enforce the ’815 Patent (and other patents) in this District, including Abbott Labs External link to document
2016-01-25 130 compound Patent"), which claims the new chemical entity paricalcitol, U.S. Patent No. 5,246,925 ("…quot;Ancillary Patents," which included the '815 Patent, and 30 other patents also not subject…[i]t is the compound patent [the '497 Patent] that is the gatekeeper patent, without a license to…#39; relationship over U.S. Patent No. 5,597,815 ("the '815 patent"). Specifically, WashU…obtained a portfolio of patents relating to paricalcitol. Among these are U.S. Patent No. 5~587,497 (" External link to document
2014-02-27 16 itself; of U.S. Patent No. 5,246,925 (“the ’925 secondary hyperparathyroidism patent”), which claims … in U.S. Patent No. 5,597,815 (“the ’815 patent”). 2. The ’815 patent is directed…family of patents, including a patent directed to the paricalcitol compound (the ’497 compound patent) and…hyperparathyroidism patent). The ’497 and ’925 patents were assigned to WARF, as were dozens of other patent families…owner of the dominating U.S. Patent No. 5,587,497 (“the ’497 compound patent”), which claims the paricalcitol External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.